Scientist working in a lab



Diversified Pipeline of Neurotherapies

Anchored by our commitment to reimagine treatments for the most urgently needed and underserved neurological and psychiatric disorders, we are building a pipeline of neuromodulators that promote balance and control of the central nervous system.

Our pipeline targets key neurochemical processes that make the central nervous system so challenging to treat.

Our Pipeline

Adamis logo PRECLINICAL TOX STUDIES IND FILED PHASE 1 PHASE 2 PHASE 3 COMMERCIAL
SYMJEPI (Anaphylaxis)
ZIMHI (Opioid Overdose)
DPI-125 (Opioid Use Disorder)
DPI-221 (Benign Prostatic Hyperplasia)
DPI-289 (Parkinson’s Disease)

Recent Publications:

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.